Janus Henderson Group PLC Akero Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,876,253 shares of AKRO stock, worth $237 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,876,253
Previous 6,121,970
12.32%
Holding current value
$237 Million
Previous $155 Million
4.32%
% of portfolio
0.09%
Previous 0.09%
Shares
21 transactions
Others Institutions Holding AKRO
# of Institutions
172Shares Held
72.6MCall Options Held
178KPut Options Held
164K-
Black Rock Inc. New York, NY5.59MShares$192 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$187 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$180 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$176 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.15MShares$143 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.6B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...